TY  - JOUR
AU  - de Bono, Johann S
AU  - Mehra, Niven
AU  - Scagliotti, Giorgio V
AU  - Castro, Elena
AU  - Dorff, Tanya
AU  - Stirling, Adam
AU  - Stenzl, Arnulf
AU  - Fleming, Mark T
AU  - Higano, Celestia S
AU  - Saad, Fred
AU  - Buttigliero, Consuelo
AU  - van Oort, Inge M
AU  - Laird, A Douglas
AU  - Mata, Marielena
AU  - Chen, Hsiang-Chun
AU  - Healy, Cynthia G
AU  - Czibere, Akos
AU  - Fizazi, Karim
PY  - 2021
DO  - 10.1016/S1470-2045(21)00376-4
UR  - http://hdl.handle.net/10668/18370
T2  - The Lancet. Oncology
AB  - Poly(ADP-ribose) polymerase (PARP) inhibitors have antitumour activity against metastatic castration-resistant prostate cancers with DNA damage response (DDR) alterations in genes involved directly or indirectly in homologous recombination repair...
LA  - en
KW  - Aged
KW  - Antineoplastic Agents
KW  - DNA Repair
KW  - Drug-Related Side Effects and Adverse Reactions
KW  - Humans
KW  - Male
KW  - Middle Aged
KW  - Mutation
KW  - Neoplasm Metastasis
KW  - Phthalazines
KW  - Poly(ADP-ribose) Polymerase Inhibitors
KW  - Prostatic Neoplasms, Castration-Resistant
KW  - Response Evaluation Criteria in Solid Tumors
KW  - Survival Analysis
TI  - Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial.
TY  - research article
VL  - 22
ER  -